Lymphoma-associated hemophagocytic syndrome: a retrospective study from a single center

Reference

• George MR. Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med. 2014;5:69–86.
   PubMedGoogle Scholar
• Ramos-Casals M, Brito- Zerón P, López -Guillermo A, et al. Adult haemophagocytic syndrome. The Lancet. 2014;383(9927):1503–1516.
   PubMed Web of Science ®Google Scholar
• Allory Y, Challine D, Haioun C, et al. Bone marrow involvement in lymphomas With hemophagocytic syndrome at presentation. Am J Surg Pathol 2001;25(7):865–874.
   PubMed Web of Science ®Google Scholar
• Kumakura S. Hemophagocytic syndrome. Intern Med. 2005;44:278–280.
   PubMed Web of Science ®Google Scholar
• Cheung MM, Chan JK, Lau WH, et al. Primary non-hodgkin’s lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol. 1998;16:70–77.
   PubMed Web of Science ®Google Scholar
• Falini B, Pileri S, De Solas I, et al. Peripheral T-cell lymphoma associated with hemophagocytic syndrome [see comments]. Blood. 1990;75:434–444.
   PubMed Web of Science ®Google Scholar
• Florena AM, Iannitto E, Quintini G, et al. Bone marrow biopsy in hemophagocytic syndrome. Virchows Arch. 2002;441:335–344.
   PubMed Web of Science ®Google Scholar
• Shimazaki C, Inaba T, Shimura K, et al. B-cell lymphoma associated with haemophagocytic syndrome: a clinical, immunological and cytogenetic study. Br J Haematol 1999;104:672–679.
   PubMed Web of Science ®Google Scholar
• Li F, Li P, Zhang R, et al. Identification of clinical features of lymphoma-associated hemophagocytic syndrome (LAHS): An analysis of 69 patients with hemophagocytic syndrome from a single-center in central region of China. Medical Oncology. 2014;31:902.
   PubMed Web of Science ®Google Scholar
• Han AR, Lee HR, Park BB, et al. Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. Ann Hematol 2007;86(7):493–498.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Miura I, Chubachi A, et al. A clinicopathological study of 20 patients with T/natural killer (NK)-cell lymphoma-associated hemophagocytic syndrome with special reference to nasal and nasal-type NK/T-cell lymphoma. Int J Hematol 2001;74:303–308.
   PubMed Web of Science ®Google Scholar
• Li N, Zhang L, Liu J, et al. A clinical study of 21 patients with hemophagocytic syndrome in 295 cases diagnosed with nasal type, extranodal nature killer/T cell lymphoma. Cancer Biol Ther 2017;18(4):252–256.
   PubMed Web of Science ®Google Scholar
• Bigenwald C, Fardet L, Coppo P, et al. A comprehensive analysis of lymphoma-associated haemophagocytic syndrome in a large French multicentre cohort detects some clues to improve prognosis. Br J Haematol 2018;183(1):68–75.
   PubMed Web of Science ®Google Scholar
• Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumors of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102:83–87.
   PubMedGoogle Scholar
• Henter JI, Elinder G, Ost A. The FHL study group of the histiocyte society. diagnostic guidelines for hemophagocytic lymphohistiocytosis. Semin Oncol. 1991;18(1):29–33.
   PubMed Web of Science ®Google Scholar
• Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–131.
   PubMed Web of Science ®Google Scholar
• Chubachi A, Miura AB. Lymphoma-associated hemophagocytic syndrome in adults: a review of the literature. Rinsho Ketsueki. 1994;35:837–845.
   PubMedGoogle Scholar
• Henter JI, Arico M, Egeler M, et al. HLH-94: A treatment protocol for hemophagocytic lymphohistiocytosis. Med Pediatr Oncol 1997;28:342–347.
   PubMedGoogle Scholar
• Sano H, Kobayashi R, Tanaka J, et al. ATF7IP as a novel PDGFRB fusion partner in acute lymphoblastic leukaemia in children. Br J Haematol 2014;165:836–841.
   PubMed Web of Science ®Google Scholar
• Jia J, Song YQ, Lin NG, et al. Clinical features and survival of extranodal natural killer/T cell lymphoma with and without hemophagocytic syndrome. Ann Hematol 2016;95(12):2023–2031.
   PubMed Web of Science ®Google Scholar
• Li N, Jiang M, Wu WC, et al. How to identify patients at high risk of developing nasal-type, extranodal nature killer/T-cell lymphoma-associated hemophagocytic syndrome. Front Oncol. 2021;11:704962.
   PubMed Web of Science ®Google Scholar
• Weaver LK, Behrens EM. Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis. Curr Opin Rheumatol. 2014;26:562–569.
   PubMed Web of Science ®Google Scholar
• Bhagwati NS, Oiseth SJ, Abebe LS, et al. Intravascular lymphoma associated with hemophagocytic syndrome: a rare but aggressive clinical entity. Ann Hematol 2004;83:247–250.
   PubMed Web of Science ®Google Scholar
• Yu JT, Wang CY, Yang Y, et al. Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution. Ann Hematol 2013;92(11):1529–1536.
   PubMed Web of Science ®Google Scholar
• Bhatt NS, Oshrine B, An Talano J. Hemophagocytic lymphohistiocytosis in adults. Leuk Lymphoma. 2019;60(1):19–28.
   PubMed Web of Science ®Google Scholar
• Lei KI, Chan LY, Chan WY, et al. Quantitative analysis of circulating cell-free epstein-barr virus (EBV) DNA levels in patients with EBV -associated lymphoid malignancies. Br J Haematol. 2000;111(1):239–246.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang H, Wang JH, et al. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase. Oncotarget. 2015;6(30):30317–30326.
   PubMed Web of Science ®Google Scholar
• Fei Q, Tian XK, Wu J, et al. Prognostic significance of epstein–barr virus DNA in NK/T-cell lymphoma: a meta-analysis. Onco Targets Ther. 2018;Volume 11:997–1004.
   Web of Science ®Google Scholar
• Castillo JJ, Beltran BE, Miranda RN, et al. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management. Am J Hematol 2018;93(7):953–962.
   PubMed Web of Science ®Google Scholar
• Wykes MN, Lewin SR. Immune checkpoint blockade in infectious diseases. Nat Rev Immunol. 2018;18(2):91–104.
   PubMed Web of Science ®Google Scholar
• Ishii E, Ohga S, Imashuku S, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 2007;86:58–65.
   PubMed Web of Science ®Google Scholar
• Liu PP, Pan XY, Chen C, et al. Nivolumab treatment of relapsed/refractory epstein-barr virus-associated hemophagocytic lymphohistiocytosis in adults. Blood. 2020;135(11):826–833.
   PubMed Web of Science ®Google Scholar
• Zoref-Lorenz A, Murakami J, Hofstetter L, et al. An improved index for diagnosis and mortality prediction in malignancy associated hemophagocytic lymphohistiocytosis. Blood. 2021;139(7):1098–1110.
   Web of Science ®Google Scholar
• Larroche C, Mouthon L. Pathogenesis of hemophagocytic syndrome (HPS). Autoimmun Rev. 2004;3:69–75.
   PubMed Web of Science ®Google Scholar
• Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood. 2015;125:2908–2914.
   PubMed Web of Science ®Google Scholar
• Johnson TS, Terrell CE, Millen SH, et al. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. The Journal of Immunology. 2014;192:84–91.
   PubMed Web of Science ®Google Scholar
• Filipovich AH. Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematol Am Soc Hematol Educ Program. 2009;1:127–131.
   Google Scholar
• Broglie L, Pommert L, Rao S, et al. Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood Advances. 2017;1(19):1533–1536.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang Y, Wu L, et al. Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis. Haematologica. 2020;105(5):e210–e212.
   PubMed Web of Science ®Google Scholar
• Slostad J, Hoversten P, Haddox CL, et al. Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: a single patient experience. Am J Hematol 2018;93(2):e47–e49.
   PubMed Web of Science ®Google Scholar
• Satzger I, Ivanyi P, Länger F, et al. Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab. Eur J Cancer. 2018;93:150–153.
   PubMed Web of Science ®Google Scholar
• Malissen N, Lacotte J, Du-Thanh A, et al. Macrophage activation syndrome: a new complication of checkpoint inhibitors. Eur J Cancer. 2017;77:88–89.
   PubMed Web of Science ®Google Scholar
• Takeshita M, Anai S, Mishima S, et al. Coincidence of immunotherapyassociated hemophagocytic syndrome and rapid tumor regression. Ann Oncol. 2017;28(1):186–189.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities. Nature Reviews Clinical Oncology. 2018;15:47–62.
   PubMed Web of Science ®Google Scholar